Two new studies from researchers at MIT and elsewhere have described “the machine-learning algorithms they developed to screen bacterial genomes and identify proteins that are involved in protecting the microorganisms against viral invaders,” reports Miryam Naddaf for Nature. “There’s a hope that maybe there’s a next generation of molecular tools that would come from some of these new systems,” says Prof. Michael Laub.
Writing for Forbes, Senior Lecturer Guadalupe Hayes-Mota 08, SM '16, MBA '16 explores how businesses can best prepare for the rapid advancements underway in the field of neurotechnology. “I believe that one of the most important steps companies can take regarding this emerging technology is to act now, without waiting for regulatory clarity first,” writes Hayes-Mota. “Treat neural data as categorically sensitive from day one—not because you are forced to, but because you understand that operating this close to the human mind demands a higher threshold of trust than almost any technology before it.”
Prof. Pat Pataranutaporn speaks with The Guardian reporter Andrew Gregory about the lack of safety warnings and disclaimers in AI overviews, specifically in AI-generated health materials. “The absence of disclaimers when users are initially served medical information creates several critical dangers,” says Pataranutaporn. “Disclaimers serve as a crucial intervention point. They disrupt this automatic trust and prompt users to engage more critically with the information they receive.”
A new study by researchers at MIT and elsewhere has found a correlation between addiction and eye care, reports Hadley Barndollar for MassLive. “The study found nearly half of the patients with opioid use disorder being treated for the eye infection were eligible to initiate medication-assisted treatment,” explains Barndollar. “But medications were only initiated when an addiction consult occurred, highlighting how much more eye doctors responding to emergency rooms can offer patients beyond vision care.”
Senior Research Scientist Leo Anthony Celi speaks with New York Times reporter Gina Kolata about the use of AI in health care. “The real concern isn’t AI itself,” says Celi. “It’s the AI is being deployed to optimize a profoundly broken system rather than to reimagine it.”
Prof. Marzyeh Ghassemi and Monica Agrawal PhD '23 speak with Boston Globe reporter Hiawatha Bray about the risks on relying solely on AI for medical information. “What I’m really, really worried about is economically disadvantaged communities,” says Ghassemi. “You might not have access to a health care professional who you can quickly call and say, ‘Hey… Should I listen to this?’”
In an appearance on the national "Diabetics Doing Things" podcast, MIT President Sally Kornbluth and Johns Hopkins University President Ron Daniels discuss their experience as Type 1 diabetics, the importance of scientific research to diagnoses and treatments that have impacted millions of fellow Type 1 diabetics across the country, and the impact on their own lives of decades of advances made at leading research universities like theirs. In conversation with host Rob Howe, they reflect on the salience of standing up for the scientific enterprise.
Prof. Lonnie Petersen speaks with Benjamin Rachlin, executive editor of MIT Horizon, about the future of space medicine in an article for The Boston Globe. “The next generation of flight surgeons might work from orbit. They might accompany a crew on a long-term mission, like a medic with a platoon,” writes Rachlin. “There is no standard yet for medical care in space. Doctors are inventing it.” Petersen notes that: “Space is like New York. If you can make it there, you can make it anywhere.”
MassLive reporter Scott Kirsner spotlights Claire Beskin MBA '22, CEO and founder of Empallo, a virtual clinic for heart care aimed at preventing cardiac issues before they happen. “It handles everything from scheduling to prescriptions to billing,” writes Kirsner. “Empallo’s approach, Beskin said, is ‘virtual first,’ meaning it tries to give patients an online consult with a doctor when possible, and send them into the office when necessary.”
Prof. Jonathan Gruber speaks with David Frum from The Atlantic’s “The David Frum Show” to shed light on the American healthcare system and health care disparities. “The issue in the U.S. is there are the haves and the have-nots—the haves get comparable health care to the rest of the world at a much higher price; the have-nots get worse health care at a much higher price,” says Gruber. “There’s really two fundamental challenges in U.S. health care: There’s disparities, and there’s costs.”
Prof. Hugh Herr speaks with Bloomberg Businessweek Daily host Carol Massar and Tim Stenovec about his work creating bionic limbs that combine human physiology with electromechanics. “I really realized how limited the current prosthetic technology was and I dedicated my life as a young man to really advance the field and enable extraordinary technology that will allow people to do what they want again, to move again and have the bodies that they seek," says Herr.
Writing for Forbes, Senior Lecturer Guadalupe Hayes-Mota 08, SM '16, MBA '16 explains the CARES framework, a new model for founders looking to integrate ethics into their company. “Biotechnology can cure, extend and transform life,” writes Hayes-Mota. “But based on my experiences, its full potential can only be realized when innovation and ethics advance together. To every scientist-founder at the edge of discovery: How can your business plan not only explain how you’ll succeed, but also why your success should exist?”
Prof. Linda Griffith speaks with Science Friday host Flora Lichtman about her work studying endometriosis. “I did a lot of things in the regenerative medicine space. But I had an epiphany that there’s so many chronic and inflammatory disease that we don’t know how to treat so I started building models of human organs and tissues in the lab using what we called microfluidic chips,” Griffith explains. “When I got asked about endometriosis, it was actually a perfect application for this kind of approach because we really need to study the lesions very carefully in the lab in ways that is very hard to study in patients.”
MIT researchers have developed a new AI tool, dubbed “DrugReflector,” aimed at speeding up the drug discovery process, reports William A. Haseltine for Forbes. The researchers used DrugReflector to test tested almost 9,600 drugs in different human cell types.“This system was 17 times more accurate than older computational methods and improved as it used honest lab feedback,” writes Haseltine.
Writing for STAT, Senior Lecturer Guadalupe Hayes-Mota 08, SM '16, MBA '16 examines how the closure of local pharmacies across the country poses a significant public health risk, particularly for Americans in rural communities who, like Hayes-Mota’s father, “depend on their local pharmacy not only for medicine, but for survival.” Hayes-Mota emphasizes that “addressing this crisis requires three urgent steps: supporting underserved areas with targeted incentives and mobile or telepharmacy services, investing in the workforce through safe staffing and career pathways, and granting pharmacists provider status with expanded scope of practice.”